Ligands of peroxisome proliferator-activated receptor γ induce apoptosis in multiple myeloma
- 1 November 2004
- journal article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 15 (10) , 955-960
- https://doi.org/10.1097/00001813-200411000-00004
Abstract
The activation of proliferator-activated receptor γ (PPAR-γ) by its natural and synthetic ligands induces apoptosis in several tumor cell lines, including malignant B-lineage cells. We investigated whether treatment with pioglitazone (PGZ), rosiglitazone (RGZ) or 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) inhibited tumor cell growth in five human multiple myeloma cell lines (LP-1, U-266, RPMI-8226-S, OPM-2 and IM-9) and human bone marrow myeloma cells expressing PPAR-γ protein. MTT assays revealed growth arrest induced by the natural activator of PPAR-γ 15d-PGJ2 and a lower antiproliferative effect with thiazolidinediones (PGZ and RGZ) in a dose-dependent manner. Induction of apoptosis was indicated by Annexin-V staining. At a dose of 50 μM, 15d-PGJ2 led to a high rate of apoptosis in all cell lines (60–92%). Furthermore, induction of apoptosis in sorted bone marrow plasma cells from myeloma patients was detected. Thiazolidinediones comprise anti-myeloma activity in vitro and should be explored further for the treatment of multiple myeloma.Keywords
This publication has 25 references indexed in Scilit:
- Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusionAnti-Cancer Drugs, 2003
- Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletionZeitschrift für Krebsforschung und Klinische Onkologie, 2003
- Thalidomide analogs as emerging anti-cancer drugsAnti-Cancer Drugs, 2003
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-IIIZeitschrift für Krebsforschung und Klinische Onkologie, 2003
- RANK ligand and osteoprotegerin in myeloma bone diseaseBlood, 2003
- Role of peroxisome proliferator-activated receptor-γ in hematologic malignanciesCurrent Opinion in Hematology, 2002
- Novel Therapeutic Approach: Ligands for PPARγ and Retinoid Receptors Induce Apoptosis in bcl-2-positive Human Breast Cancer CellsBreast Cancer Research and Treatment, 2002
- Development of an EORTC questionnaire module to be used in health‐related quality‐of‐life assessment for patients with multiple myelomaBritish Journal of Haematology, 1999
- The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activationNature, 1998